Prostatic Neoplasms, Castration-Resistant
Oncology·MeSH: Prostatic Neoplasms, Castration-Resistant
Prevalence
256.0 / 100K
Incidence
111.0 / 100K/yr
11 drugs in development·5 companies·9 clinical trials
Drug Pipeline by Phase
Phase 3(7)
Phase 1(2)
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| Enzalutamide | Arcus Biosciences, Inc. (RCUS) |
Phase 4(1)
| Drug | Company |
|---|---|
| abiraterone | PFIZER INC (PFE) |
Compare drugs
Frequently asked questions
How many drugs are in development for Prostatic Neoplasms, Castration-Resistant?
BioSniper tracks 11 drugs in development for Prostatic Neoplasms, Castration-Resistant across 5 companies.
How many clinical trials target Prostatic Neoplasms, Castration-Resistant?
There are 9 clinical trials targeting Prostatic Neoplasms, Castration-Resistant tracked by BioSniper.
What is the prevalence of Prostatic Neoplasms, Castration-Resistant?
The estimated prevalence of Prostatic Neoplasms, Castration-Resistant is approximately 256.0 per 100,000 population.
Deep-dive into Prostatic Neoplasms, Castration-Resistant
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis